Rogerio A Lobo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3100558/publications.pdf

Version: 2024-02-01

99 papers	9,134 citations	66234 42 h-index	53109 85 g-index
102 all docs	102 docs citations	102 times ranked	6837 citing authors

#	Article	IF	Citations
1	Consensus on womenâ€™s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertility and Sterility, 2012, 97, 28-38.e25.	0.5	1,494
2	Executive Summary of the Stages of Reproductive Aging Workshop + 10: Addressing the Unfinished Agenda of Staging Reproductive Aging. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1159-1168.	1.8	851
3	Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy Is Associated with Significant Morbidity in Women. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1897-1899.	1.8	417
4	Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?. American Journal of Obstetrics and Gynecology, 1992, 167, 1807-1812.	0.7	399
5	Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPSâ€“Cognitive and Affective Study. PLoS Medicine, 2015, 12, e1001833.	3.9	330
6	CLINICAL REVIEW 27 Effects of Hormonal Replacement on Lipids and Lipoproteins in Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 1991, 73, 925-930.	1.8	292
7	Potential Options for Preservation of Fertility in Women. New England Journal of Medicine, 2005, 353, 64-73.	13.9	247
8	Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertility and Sterility, 2009, 92, 1025-1038.	0.5	239
9	The Importance of Diagnosing the Polycystic Ovary Syndrome. Annals of Internal Medicine, 2000, 132, 989.	2.0	236
10	Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertility and Sterility, 2003, 79, 1341-1352.	0.5	230
11	Metabolic syndrome after menopause and the role of hormones. Maturitas, 2008, 60, 10-18.	1.0	224
12	Estrogen and progestogen use in postmenopausal women. Menopause, 2008, 15, 584-602.	0.8	211
13	The diagnosis of polycystic ovary syndrome in adolescents. American Journal of Obstetrics and Gynecology, 2010, 203, 201.e1-201.e5.	0.7	205
14	Prevention of diseases after menopause. Climacteric, 2014, 17, 540-556.	1.1	197
15	Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertility and Sterility, 2001, 76, 13-24.	0.5	188
16	A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertility and Sterility, 1993, 60, 664-667.	0.5	183
17	Evidence for the Importance of Peripheral Tissue Events in the Development of Hirsutism in Polycystic Ovary Syndrome*. Journal of Clinical Endocrinology and Metabolism, 1983, 57, 393-397.	1.8	175
18	Insulin resistance in polycystic ovary syndrome. American Journal of Obstetrics and Gynecology, 1983, 147, 588-592.	0.7	174

#	Article	IF	Citations
19	Endothelial Dysfunction in PCOS: Role of Obesity and Adipose Hormones. American Journal of Medicine, 2006, 119, 356.e1-356.e6.	0.6	145
20	Clinical and laboratory predictors of clomiphene response**Supported in part by Grant HD 05932 from the National Institutes of Health, United States Public Health Service, Bethesda, Maryland, and by a grant from the Ford Foundation.. Fertility and Sterility, 1982, 37, 168-174.	0.5	143
21	The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertility and Sterility, 2004, 81, 1498-1501.	0.5	141
22	Prolactin modulation of dehydroepiandrosterone sulfate secretion. American Journal of Obstetrics and Gynecology, 1980, 138, 632-636.	0.7	115
23	Surgical menopause and cardiovascular risks. Menopause, 2007, 14, 562-566.	0.8	112
24	Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. Atherosclerosis, 2016, 254, 282-290.	0.4	105
25	The Kronos Early Estrogen Prevention Study (KEEPS). Menopause, 2019, 26, 1071-1084.	0.8	97
26	Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy Is Associated with Significant Morbidity in Women. , 0, .		94
27	Do hyperandrogenic women with normal menses have polycystic ovary syndrome?. Fertility and Sterility, 1999, 71, 319-322.	0.5	90
28	Polycystic ovaries in hirsute women with normal menses. American Journal of Medicine, 2001, 111, 602-606.	0.6	90
29	Where Are We 10 Years After the Women's Health Initiative?. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1771-1780.	1.8	89
30	Elevated subclinical atherosclerosis associated with oophorectomy is related to time since menopause rather than type of menopause. Fertility and Sterility, 2004, 82, 391-397.	0.5	86
31	Normal Ovulatory Women with Polycystic Ovaries Have Hyperandrogenic Pituitary-Ovarian Responses To Gonadotropin-Releasing Hormone-Agonist Testing*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 995-1000.	1.8	82
32	Evaluation of Cardiovascular Event Rates With Hormone Therapy in Healthy, Early Postmenopausal Women. Archives of Internal Medicine, 2004, 164, 482.	4.3	77
33	A disorder without identity: â€œHCA,â€œ â€œPCO,â€œ â€œPCOD,â€•â€œPCOS,â€•â€œSLSâ€• What are we to call it?!. Fertility and Sterility, 1995, 63, 1158-1160.	0.5	73
34	A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome. Fertility and Sterility, 2006, 86, 1669-1675.	0.5	69
35	The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women. Fertility and Sterility, 1994, 62, 1176-1180.	0.5	65
36	A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clinical Endocrinology, 2002, 57, 231-234.	1.2	63

#	Article	IF	Citations
37	Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause. JAMA Internal Medicine, 2017, 177, 1471.	2.6	59
38	6 Peripheral androgens and the role of androstanediol glucuronide. Clinics in Endocrinology and Metabolism, 1986, 15, 293-306.	1.8	57
39	Alterations in low-density lipoprotein and high-density lipoprotein subclasses among hispanic women with polycystic ovary syndrome: influence of insulin and genetic factors. Fertility and Sterility, 1999, 72, 990-995.	0.5	53
40	Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis. Fertility and Sterility, 1996, 65, 1100-1109.	0.5	52
41	A 17Î²-Estradiolâ€“Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women. Obstetrics and Gynecology, 2018, 132, 161-170.	1.2	48
42	Is 11Î²-hydroxyandrostenedione a better marker of adrenal androgen excess than dehydroepiandrosterone sulfate?. American Journal of Obstetrics and Gynecology, 1991, 165, 1837-1842.	0.7	45
43	Evidence that insulin and androgens may participate in the regulation of serum leptin levels in women. Fertility and Sterility, 1999, 72, 926-931.	0.5	45
44	Amh Measurement Versus Ovarian Ultrasound In The Diagnosis Of Polycystic Ovary Syndrome In Different Phenotypes. Endocrine Practice, 2016, 22, 287-293.	1.1	38
45	Menopausal Sexual Interest Questionnaire (MSIQ): A Unidimensional Scale for the Assessment of Sexual Interest in Postmenopausal Women. Journal of Sex and Marital Therapy, 2004, 30, 235-250.	1.0	37
46	Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause. Expert Review of Clinical Pharmacology, 2022, 15, 121-137.	1.3	33
47	A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety. Menopause, 2020, 27, 848-857.	0.8	30
48	Different mechanisms for benefit and risk of coronary heart disease and stroke in early postmenopausal women. Menopause, 2011, 18, 237-240.	0.8	30
49	Ovulation Induction in Clomiphene-Resistant Anovulatory Women: Differential Follicular Response to Purified Urinary Follicle-Stimulating Hormone (FSH)VersusPurified Urinary FSH and Luteinizing Hormone*. Journal of Clinical Endocrinology and Metabolism, 1985, 60, 922-927.	1.8	29
50	Genetic polymorphisms associated with carotid artery intima-media thickness and coronary artery calcification in women of the Kronos Early Estrogen Prevention Study. Physiological Genomics, 2013, 45, 79-88.	1.0	28
51	The association of serum androsterone glucuronide with inflammatory lesions in women with adult acne1. Journal of Endocrinological Investigation, 2002, 25, 765-768.	1.8	27
52	Endocrinology: Isolated polycystic morphology in ovum donors predicts response to ovarian stimulation*. Human Reproduction, 1995, 10, 524-528.	0.4	26
53	Does metformin induce ovulation in normoandrogenic anovulatory women?. American Journal of Obstetrics and Gynecology, 2004, 191, 1580-1584.	0.7	26
54	Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome. Endocrine, 2012, 42, 526-534.	1.1	26

#	Article	IF	Citations
55	What are the key features of importance in polycystic ovary syndrome?. Fertility and Sterility, 2003, 80, 259-261.	0.5	24
56	Lipids, clotting factors, and diabetes: Endogenous risk factors for cardiovascular disease. American Journal of Obstetrics and Gynecology, 1988, 158, 1584-1591.	0.7	23
57	Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study. Physiological Genomics, 2016, 48, 33-41.	1.0	23
58	Female Adult Acne and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. Journal of the Endocrine Society, 2022, 6, bvac003.	0.1	23
59	Does the level of serum antimÃ¼llerian hormone predict ovulatory function inÂwomen with polycystic ovary syndrome with aging?. Fertility and Sterility, 2012, 98, 1043-1046.	0.5	21
60	Different mechanisms for benefit and risk of coronary heart disease and stroke in early postmenopausal women: a hypothetical explanation. Menopause, 2011, 18, 237-40.	0.8	21
61	Characterization of metabolic changes in the phenotypes of women with polycystic ovary syndrome in a large Mediterranean population from Sicily. Clinical Endocrinology, 2019, 91, 553-560.	1.2	19
62	What is the cardioprotective role of hormone replacement therapy?. Current Atherosclerosis Reports, 2003, 5, 56-66.	2.0	16
63	Early ovarian ageing: a hypothesis: What is early ovarian ageing?. Human Reproduction, 2003, 18, 1762-1764.	0.4	16
64	The Rationale for Low-Dose Hormonal Therapy. Endocrine, 2004, 24, 217-222.	2.2	16
65	Features of polycystic ovary syndrome (PCOS) in women with functional hypothalamic amenorrhea (FHA) may be reversible with recovery of menstrual function. Gynecological Endocrinology, 2018, 34, 301-304.	0.7	16
66	Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2019, 317, R912-R920.	0.9	15
67	Formulations and Use of Androgens in Women. Mayo Clinic Proceedings, 2004, 79, S3-S7.	1.4	13
68	Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers. American Journal of Obstetrics and Gynecology, 2008, 199, 526.e1-526.e7.	0.7	12
69	Menopause and Aging. , 2019, , 322-356.e9.		12
70	Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms. Climacteric, 2019, 22, 610-616.	1.1	12
71	Kisspeptin Influence on Polycystic Ovary Syndromeâ€"a Mini Review. Reproductive Sciences, 2020, 27, 455-460.	1.1	12
72	Postmenopausal hormone replacement therapy as antiatherosclerotic therapy. Current Atherosclerosis Reports, 2002, 4, 52-58.	2.0	11

#	Article	IF	Citations
73	Prevalence of metabolic disturbances among women with polycystic ovary syndrome in different regions of Brazil. International Journal of Gynecology and Obstetrics, 2020, 151, 383-391.	1.0	11
74	Priorities in polycystic ovary syndrome. Medical Journal of Australia, 2001, 174, 554-555.	0.8	10
75	Laboratory Assessment. , 2014, , 822-850.e3.		10
76	Appropriate use of hormones should alleviate concerns of cardiovascular and breast cancer risk. Maturitas, 2005, 51, 98-109.	1.0	9
77	Evaluation of Hormonal Status. , 2019, , 887-915.e4.		8
78	Menopause and Aging. , 2009, , 325-355.		6
79	Evaluation of Hormonal Status. , 2009, , 801-823.		6
80	Low estradiol responses in oocyte donors undergoing gonadotropin stimulation do not influence clinical outcomes. Journal of Assisted Reproduction and Genetics, 2018, 35, 1675-1682.	1.2	6
81	Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and) Tj ETQq1 1 0.784314 rgBT /Overlock	1.4	6
82	Should symptomatic menopausal women be offered hormone therapy?. MedGenMed: Medscape General Medicine, 2006, 8, 40.	0.2	6
83	Menopause and Aging. , 2014, , 308-339.e8.		5
84	Utility of Ovarian Reserve Screening with Anti-MÃ¼llerian Hormone for Reproductive Age Women Deferring Pregnancy. Journal of Women's Health, 2017, 26, 345-351.	1.5	4
85	Outcomes of high-order multiple implantations in women undergoing ovum donation. , 1997, 6, 268-272.		3
86	Differences in Urinary Excretion Patterns of the hLH Beta Core Fragment in Premenopausal, Perimenopausal, and Postmenopausal Women. Menopause, 1999, 6, 290-298.	0.8	3
87	Potential pitfalls of reproductive direct-to-consumer testing. F&S Reports, 2022, 3, 3-7.	0.4	2
88	Views on Recent Trials and the Future of Hormonal Therapy. Clinical Obstetrics and Gynecology, 2004, 47, 424-427.	0.6	1
89	FOREWORD. Clinical Obstetrics and Gynecology, 2008, 51, 533.	0.6	1
90	Daniel R. Mishell Jr, MD, May 7, 1931â€“May 4, 2016. Climacteric, 2016, 19, 411-412.	1.1	1

#	Article	IF	Citations
91	Use of antiâ€MÃ¼llerian hormone testing during ovarian reserve screening to identify women at risk of polycystic ovary syndrome. International Journal of Gynecology and Obstetrics, 2016, 135, 73-76.	1.0	1
92	The Future of Therapy and the Role of Hormone Therapy. , 2007, , 875-880.		1
93	Should symptomatic menopausal women be offered hormone therapy?. MedGenMed: Medscape General Medicine, 2006, 8, 1 p preceding 35.	0.2	1
94	Outcomes of High-Order Multiple Implantations in Women Undergoing Ovum Donation. Journal of Maternal-Fetal and Neonatal Medicine, 1997, 6, 268-272.	0.7	0
95	Areas for future inquiry. Endocrinology and Metabolism Clinics of North America, 2004, 33, 761-769.	1.2	0
96	Menopausal Hormonal Therapy and Cardiovascular Disease. Current Obstetrics and Gynecology Reports, 2014, 3, 217-222.	0.3	0
97	Foreword. Journal of Steroid Biochemistry and Molecular Biology, 2014, 142, 3.	1.2	0
98	Formulations and use of androgens in women. Mayo Clinic Proceedings, 2004, 79, S3-7.	1.4	0
99	Climacteric commentaries. Endogenous estradiol and coronary calcifications in postmenopausal women. Climacteric, 2010, 13, 502-3.	1.1	0